CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 143 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01733628
NCT01733628N/ACompleted
CompareCT.gov

Evaluation Study of Hypertension as a Predictor of Efficacy Bevacizumab (BV) in Combination With Chemotherapy (CT) in Metastatic Colorectal Cancer (MCC) and Metastatic Breast Cancer (MBC).

Spanish Breast Cancer Research Group·observational·Posted Nov 27, 2012·Updated Dec 4, 2019

In Brief

An observational study for Metastatic Colorectal Cancer and Metastatic Breast Cancer. Completed, enrolled 143 participants across 10 sites.

Detailed Summary

This is a multicenter, post-authorization observational with prospective follow-up (EPA-SP) study. Will be involved 137 metastatic breast cancer patients or metastatic colorectal cancer. The hypertension will be evaluated as a predictor of efficacy of bevacizumab associated with chemotherapy, in terms of progression-free survival (PFS) (Main endpoint). The duration of the study will be approximately 42 months.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Colorectal Cancer, Metastatic Breast Cancer
CountriesSpain
CollaboratorsRoche Farma, S.A

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 27, 2012
Enrollment StartOct 23, 2012
Primary CompletionDec 19, 2017
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 13.6 years ago